What is the current Avidity Biosciences (RNA) stock price?

Avidity Biosciences is currently trading at $13.01, a change of -4.69% from the previous close. The 52-week range spans from $11.40 to $16.77.

What is the analyst consensus on Avidity Biosciences?

3 analysts rate Avidity Biosciences as None on average. The mean price target is $25.00, implying +92.2% from the current price.

Where can I buy Avidity Biosciences stock?

You can buy Avidity Biosciences (RNA) at any regulated online broker. Compare the best options (Trade Republic, Scalable Capital, Interactive Brokers, DEGIRO) in our broker comparison by fees, savings plans, and available exchanges.

← Back to Screener

Sector: Healthcare

Open in Terminal → RNALive chart · Key metrics · News · Smart money

Avidity Biosciences

RNA Micro Cap

Healthcare · Biotechnology

Updated: Jul 6, 2026, 22:20 UTC

$13.01

-4.69% today

52W: $11.40 – $16.77

52W Low: $11.40 Position: 30% 52W High: $16.77

🔗 Compare Brokers

Price Chart

Key Metrics

P/E Ratio

—

Price-to-Earnings

Forward P/E

—

Forward Price/Earnings

P/S Ratio

6.07x

Price-to-Sales

EV/EBITDA

0.54x

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$222.5M

Market Capitalization

Revenue Growth

1148.3%

YoY Revenue Growth

Profit Margin

-159.99%

Net profit margin

ROE

—

Return on Equity

Beta

—

Market sensitivity

Short Interest

—

% of float sold short

Avg. Volume

299,650

Average daily volume

Valuation Analysis

Signal

N/A

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

None

3 analysts

Avg. Price Target

$25.00

+92.16% upside

Target Range

$25.00 – $25.00

About the Company

Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.

Sector: Healthcare Industry: Biotechnology Country: United States Exchange: NMS

Avidity Biosciences Stock at a Glance

Avidity Biosciences (RNA) is currently trading at $13.01 with a market capitalization of $222.5M. The 52-week range spans from $11.40 to $16.77; the current price is 22.4% below the yearly high. Year-over-year revenue growth stands at +1148.3%.

💰 Dividend

Avidity Biosciences currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

3 analysts rate Avidity Biosciences (RNA) on consensus: None. The average price target is $25.00, implying +92.16% from the current price. Analyst price targets range from $25.00 to $25.00.

Avidity Biosciences: The Investment Case in Detail

Avidity Biosciences (RNA) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Top-line momentum is unusually strong with revenue expanding 1148.3% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind.

The Bear Case

Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders.

Valuation in Context

The EV/EBITDA multiple of 0.54x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.